Loading...
NPI 1740221225 · Palmer, AK · Medical Oncology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
John Zimmermann is a medical oncology physician provider located in Palmer, Alaska. This profile covers 39 Medicare and 1 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | John Zimmermann |
| Address | 2490 S Woodworth Loop |
| City | Palmer |
| State | AK |
| ZIP | 99645 |
| Taxonomy | Medical Oncology Physician |
| NPI Enumerated | June 8, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $1.2M |
| Medicaid | $570 |
This is an oncology-focused practice: the Medicare revenue mix is dominated by high-cost infused therapies and radiation delivery codes, consistent with a medical oncology practice that administers immunotherapy and supportive biologics and also bills technical delivery of radiation. The top Medicare revenue drivers are J9271, J0897, and G6015, reflecting pembrolizumab infusions, denosumab administrations, and intensity-modulated treatment delivery respectively, alongside typical chemotherapy/infusion and E/M codes in the top 25.
Medicare revenue is highly concentrated in a few items: the top 3 Medicare codes by revenue account for 80.7% of this provider's total Medicare revenue, with J9271 at 53.0%, J0897 at 15.1%, and G6015 at 12.5%. This concentration indicates that a majority of Medicare dollars are tied to a small set of infusion and radiation services rather than spread across many outpatient procedures.
By scale the provider is effectively Medicare-centric: lifetime Medicare revenue is $1.2M versus total Medicaid revenue of $565, so Medicaid represents a de minimis share of billed revenue. The precomputed top-3 Medicaid share is 100.0%, and that Medicaid volume is entirely from 99213, indicating almost no Medicaid-based infusion or specialty drug billing on record.
Competitive standing for the highest Medicare drug and treatment codes is mixed: J0897 ranks #1148 of 10057 (88th percentile) nationally, indicating relatively high volume for denosumab compared with peers; J9271 ranks #719 of 1841 (61th percentile) and G6015 ranks #727 of 1429 (49th percentile), both characterized in the source as typical, unremarkable volumes. In plain terms, the provider is not a national outlier driving pembrolizumab use but shows above-average activity for denosumab administration.
Office visit and infusion-support activity is visible and above-average for certain E/M levels: 99214 appears with 303 claims and ranks #99287 of 479517 (79th percentile) and 99215 appears with 160 claims and ranks #16403 of 145531 (89th percentile), while 99213 (Medicare) ranks #178587 of 457151 (61th percentile). These percentiles are consistent with an outpatient oncology clinic that couples medication administration with moderate- and high-complexity established-patient visits.
The Medicaid footprint is extremely small and relatively low versus in‑state peers: Medicaid 99213 accounts for $560 and 100.0% of Medicaid revenue, and it ranks #429 of 485 providers in-state (11th percentile). The combination of a $565 total Medicaid lifetime revenue figure and a low in‑state rank signals that this provider does not rely on Medicaid volume for its oncology practice.
Operational dependency on a single high-revenue drug is notable: J9271 alone represents 53.0% of Medicare revenue, so payer coverage, pricing, or utilization shifts for this drug would materially affect the provider's Medicare revenue mix. Other revenue lines (denosumab and IMRT delivery) provide some diversification but the practice remains concentrated in a few high-cost services.
The provider is long-tenured in the registry, with NPI enumeration dated 2006-06-08 (~20 years ago), which supports that these billing patterns reflect an established practice rather than a newly formed operation. Tenure combined with the concentrated Medicare revenue profile points to an experienced oncology clinician embedded in the local market with a specialized service mix.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
39 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | 14,600 | $40 | $627.8K |
| J0897 | Injection, denosumab, 1 mg | 9,960 | $20 | $179.3K |
| G6015 | Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session | 520 | $290 | $148.5K |
| Q5122 | Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg | 400 | $100 | $40.4K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 300 | $90 | $28.5K |
| 77014 | N/A | 420 | $60 | $25K |
| 99215 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the… | 160 | $130 | $21.4K |
| J1439 | Injection, ferric carboxymaltose, 1 mg | 21,000 | $1 | $21K |
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 210 | $100 | $20.5K |
| J1454 | Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | 30 | $330 | $10.6K |
Showing 1–10 of 39
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 39 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
39 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J9271 | 7 | 10 | 13,300 | $40 | $609.5K |
| G6015 | 5 | 10 | 520 | $310 | $206.5K |
| J0897 | 4 | 30 | 2,700 | $20 | $82.7K |
| 77014 | 10 | 10 | 680 | $60 | $63.5K |
| Q5122 | 1 | 10 | 370 | $100 | $36.9K |
| 96413 | 13 | 20 | 230 | $110 | $30.2K |
| J1454 | 3 | 10 | 50 | $350 | $18.4K |
| 99214 | 177 | 1,210 | 90 | $100 | $16.2K |
| J1439 | 1 | 10 | 19,130 | $1 | $15.8K |
| 77336 | 6 | 10 | 180 | $70 | $13.4K |
Showing 1–10 of 39
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
1 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 30 | $20 | $560 |
How this provider's Medicaid billing volume and revenue compare to other Alaska providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Alaska median
1 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 429 | 490 | 680 | $260 | $1M |
Other providers in the same ZIP code as John Zimmermann, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.